Jubilant Pharmova Statistics

Total Valuation

NSE:JUBLPHARMA has a market cap or net worth of INR 178.30 billion. The enterprise value is 194.55 billion.

Market Cap	178.30B
Enterprise Value	194.55B

Important Dates

The next estimated earnings date is Friday, July 18, 2025.

Earnings Date	Jul 18, 2025
Ex-Dividend Date	Jul 25, 2025

Share Statistics

Current Share Class	158.35M
Shares Outstanding	n/a
Shares Change (YoY)	-0.02%
Shares Change (QoQ)	+0.02%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	64.51M

Valuation Ratios

The trailing PE ratio is 21.24 and the forward PE ratio is 31.53.

PE Ratio	21.24
Forward PE	31.53
PS Ratio	2.46
PB Ratio	2.86
P/TBV Ratio	6.81
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 16.58, with an EV/FCF ratio of -447.25.

EV / Earnings	23.18
EV / Sales	2.69
EV / EBITDA	16.58
EV / EBIT	24.18
EV / FCF	-447.25

Financial Position

The company has a current ratio of 1.65, with a Debt / Equity ratio of 0.44.

Current Ratio	1.65
Quick Ratio	0.92
Debt / Equity	0.44
Debt / EBITDA	2.33
Debt / FCF	-62.78
Interest Coverage	3.35

Financial Efficiency

Return on equity (ROE) is 14.35% and return on invested capital (ROIC) is 5.57%.

Return on Equity (ROE)	14.35%
Return on Assets (ROA)	4.14%
Return on Invested Capital (ROIC)	5.57%
Return on Capital Employed (ROCE)	7.60%
Revenue Per Employee	13.40M
Profits Per Employee	1.55M
Employee Count	5,399
Asset Turnover	0.60
Inventory Turnover	1.90

Taxes

In the past 12 months, NSE:JUBLPHARMA has paid 1.44 billion in taxes.

Income Tax	1.44B
Effective Tax Rate	14.72%

Stock Price Statistics

The stock price has increased by +48.95% in the last 52 weeks. The beta is 0.80, so NSE:JUBLPHARMA's price volatility has been lower than the market average.

Beta (5Y)	0.80
52-Week Price Change	+48.95%
50-Day Moving Average	992.51
200-Day Moving Average	1,038.52
Relative Strength Index (RSI)	61.17
Average Volume (20 Days)	796,696

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, NSE:JUBLPHARMA had revenue of INR 72.35 billion and earned 8.39 billion in profits. Earnings per share was 52.85.

Revenue	72.35B
Gross Profit	49.18B
Operating Income	8.05B
Pretax Income	9.81B
Net Income	8.39B
EBITDA	11.74B
EBIT	8.05B
Earnings Per Share (EPS)	52.85

Full Income Statement

Balance Sheet

The company has 10.89 billion in cash and 27.31 billion in debt, giving a net cash position of -16.42 billion.

Cash & Cash Equivalents	10.89B
Total Debt	27.31B
Net Cash	-16.42B
Net Cash Per Share	n/a
Equity (Book Value)	62.39B
Book Value Per Share	395.41
Working Capital	14.13B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 10.72 billion and capital expenditures -11.16 billion, giving a free cash flow of -435.00 million.

Operating Cash Flow	10.72B
Capital Expenditures	-11.16B
Free Cash Flow	-435.00M
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 67.97%, with operating and profit margins of 11.13% and 11.60%.

Gross Margin	67.97%
Operating Margin	11.13%
Pretax Margin	13.55%
Profit Margin	11.60%
EBITDA Margin	16.22%
EBIT Margin	11.13%
FCF Margin	n/a

Dividends & Yields

This stock pays an annual dividend of 5.00, which amounts to a dividend yield of 0.46%.

Dividend Per Share	5.00
Dividend Yield	0.46%
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	9.48%
Buyback Yield	0.02%
Shareholder Yield	0.48%
Earnings Yield	4.71%
FCF Yield	-0.24%

Dividend Details

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside

Stock Splits

The last stock split was on March 17, 2006. It was a forward split with a ratio of 5.

Last Split Date	Mar 17, 2006
Split Type	Forward
Split Ratio	5

Scores

Altman Z-Score	n/a
Piotroski F-Score	7